Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $1.60 Analyst target: $15.00 Upside: 837.50%
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. The company is headquartered in Boston, Massachusetts.
See the full interactive analysis & chart →Informational only — not investment advice.